Viking Therapeutics Inc. (VKTX)

8.26 -1.02 (-10.991%)

IEX Real-Time Price

March 22, 2019 EST.

NASDAQ Capital Market : Healthcare

Prev Close 9.28

Price Open 9.16

Volume: 3.94M

Avg Volume: 3.4M

Market Cap: 594.6M

P/E Ratio -20.15

52 Wk Range 3.69-24



VKTX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
57.98M
19.81M
2.50
34.17%

2018-09-28
57.98M
15.36M
2.36
26.49%

2018-09-14
57.98M
10.45M
4.87
18.03%

2018-08-31
57.98M
9.93M
5.34
17.12%




VKTX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-07
Q3 2018
AMC
-0.11 (6)
-0.11
0.00

2018-08-09
Q2 2018
AMC
-0.11 (6)
-0.13
-0.02

2018-05-09
Q1 2018
N/A
-0.11 (3)
-0.10
0.01

2018-03-20
Q4 2017
N/A
-0.19 (3)
-0.10
0.01

News

Conatus flop fails to move NASH players (2019-03-22 10:31 SeekingAlpha)

The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne…

 


Statistics

Shares Outstanding: 71.99M

Top 15 Institution Percent: 103.80

Price To Sales: N/A

Price To Book: 2.00

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -13.60

Return On Equity: -14.18

Profit Margin: N/A

Price History

Beta: 2.72

50-day Moving Avg: 8.35

200-day Moving Avg: 10.81

YTD Change: -0.72

5-day Change: -2.82

1-month Change: -4.07

3-month Change: 15.36

6-month Change: -57.18

1-year Change: 81.14

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Viking Therapeutics Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.vikingtherapeutics.com

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.